A Review of the Past, Present, and Future Directions of Neoplasia  by Rehemtulla, Alnawaz & Ross, Brian D.
A Review of the Past, Present, and Future
Directions of Neoplasia
Alnawaz Rehemtulla, Brian D. RossQ1
This past year, we have seen a phenomenal growth in the
number of articles submitted to Neoplasia, breaking all pre-
vious records. While the number of submitted articles
continues to rise on an annual basis, the editorial office con-
tinues to maintain a very high standard of scientific quality,
which has been consistently maintained over the last
7 years. Since its inception back in 1999, Neoplasia has
been a trend-setting, broad-based cancer journal and was,
in fact, the first journal to offer online web-based manuscript
submission and peer review using our custom-designed ap-
plication JournalSoft. Although the use of web-based manu-
script processing is becomingmore of a standard rather than
the exception, the process utilized byNeoplasia offers many
unique features, which were developed by scientists to
facilitate the scientific process. One of these features, which
authors who have had works published in Neoplasia are
familiar with, is that, during the peer review process, Journal-
Soft offers authors the ability to read reviewers’ comments
as they are submitted. This provides the authors with the
opportunity to think about the comments and even begin to
address the concerns prior to the receipt of additional
reviewers’ comments. JournalSoft also provides an oppor-
tunity for the authors to reply to the anonymous reviewer(s)
in a point-by-point fashion prior to editorial decision. This
provides for a critical dialogue exchange, with the net benefit
of improving the quality of the science and the speed of the
review process. It is these types of innovations which make
Neoplasia the first choice of a growing list of authors.
During the past 3 years,Neoplasia has published consistent,
broad-based articles from diverse areas of cancer research, as
shown in Table 1. This table lists articles by general topic area
for publication years 2003–2005.Readily apparent fromTable 1
is the fact that the number of articles in each category has been
growing over the past 3 years. Moreover, the number of
published articles increased by 21% in 2004 and increased
again by 38% in 2005, revealing the rapid growth and impact
Neoplasia has had in the research community.
In the upcoming year (volume 8, 2006), we will be initiating a
new open access policy forNeoplasia, wherein all publishedman-
uscripts will be made rapidly available online for worldwide
readership. This will provide authors the widest possible reader-
ship, ensuring that articles published in Neoplasia will have the
largest impact possible on the cancer research community. Neo-
plasia is committed to meeting the changing concerns and
needs of cancer investigators, and this is why we believe that
open access for all published articles will be greatly beneficial.
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